Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 10/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.43 |
| ▸ | GRM5 | P41594 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3582326 | 0.83 | MEN1 (0.52) | GRM5LMNASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL3577903 | 0.82 | NOTUM (0.49) | LMNASMN1; SMN2KDM4EMEN1MAPK1 | |
| SCHEMBL3579042 | 0.76 | ABL1 (0.46) | LMNASMN1; SMN2KDM4EMEN1MAPK1 | |
| SCHEMBL3581625 | 0.73 | MEN1 (0.46) | ABCG2ABCB1LMNASMN1; SMN2KDM4E | |
| SCHEMBL3569227 | 0.73 | FLT3 (0.45) | ABCG2ABCB1LMNASMN1; SMN2KDM4E | |
| SCHEMBL3579704 | 0.73 | RHOA (0.47) | ABCG2ABCB1LMNASMN1; SMN2KDM4E | |
| SCHEMBL2952613 | 0.72 | GRM5 (0.48) | GRM5KDM4EMAPK1ALDH1A1 | |
| SCHEMBL15688270 | 0.71 | EGFR (0.54) | ABCG2ABCB1LMNASMN1; SMN2KDM4E | |
| SCHEMBL31178105 | 0.71 | ALDH1A1 (0.36) | GRM5LMNASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL199306 | 0.71 | ALDH1A1 (0.65) | GRM5LMNASMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S | 2010-02-11 | — | — | US | claimed |
| EP-2114916-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2009-11-11 | — | — | EP | claimed |
| WO-2008092942-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-08-07 | — | — | WO | claimed |
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S | 2010-02-11 | — | — | US | disclosed |
| EP-2114916-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008092942-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNA3, KCNQ1 | ABCG2 494/4885ABCB1 388/4885GRM5 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.